|
- 积分
- 299
- 威望
- 299
- 包包
- 1702
|
Mol Ther. 2011 Mar;19(3):584-93. Epub 2010 Nov 30.6 c, \( H+ p( x- J
% U( P$ x" L: G* P; U; \6 g1 |
Generation of HIV-1 Resistant and Functional Macrophages From Hematopoietic Stem Cell-derived Induced Pluripotent Stem Cells.1 o2 b, }" x1 O5 W8 }! E8 V# @) T
Kambal A, Mitchell G, Cary W, Gruenloh W, Jung Y, Kalomoiris S, Nacey C, McGee J, Lindsey M, Fury B, Bauer G, Nolta JA, Anderson JS.
/ l- D3 I% o! {, m3 q/ h- |5 O* ?" H+ I# ^$ _/ g# E" Z2 ]6 D4 Y
Stem Cell Program, Department of Internal Medicine, University of California, Davis, Sacramento, California, USA.- w( \5 T1 [- h2 b* [9 a2 ] v! ^
9 `. ~$ c- T9 x3 ]Abstract
# H" h9 k5 }+ J: zInduced pluripotent stem cells (iPSCs) have radically advanced the field of regenerative medicine by making possible the production of patient-specific pluripotent stem cells from adult individuals. By developing iPSCs to treat HIV, there is the potential for generating a continuous supply of therapeutic cells for transplantation into HIV-infected patients. In this study, we have used human hematopoietic stem cells (HSCs) to generate anti-HIV gene expressing iPSCs for HIV gene therapy. HSCs were dedifferentiated into continuously growing iPSC lines with four reprogramming factors and a combination anti-HIV lentiviral vector containing a CCR5 short hairpin RNA (shRNA) and a human/rhesus chimeric TRIM5α gene. Upon directed differentiation of the anti-HIV iPSCs toward the hematopoietic lineage, a robust quantity of colony-forming CD133(+) HSCs were obtained. These cells were further differentiated into functional end-stage macrophages which displayed a normal phenotypic profile. Upon viral challenge, the anti-HIV iPSC-derived macrophages exhibited strong protection from HIV-1 infection. Here, we demonstrate the ability of iPSCs to develop into HIV-1 resistant immune cells and highlight the potential use of iPSCs for HIV gene and cellular therapies. A1 _' B+ }% b C3 r# F$ M
; _7 M' ?% j% ?# ^, d
|
-
总评分: 威望 + 2
包包 + 5
查看全部评分
|
发表于 2011-3-24 15:13
